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Introduction
The development of tension by myofi  broblasts (Mfs) promotes 
physiological tissue repair for which the contracting granu-
lation tissue of healing wounds is a paradigm (Hinz, 2007). 
However, the excessive ECM-secreting and contractile activi-
ties of Mfs contribute to progressive fi  brosis in many organs, 
such as the heart, lung, liver, kidney, and skin (Gabbiani, 2003; 
Hinz et al., 2007). The high contractile activity of Mfs is gener-
ated by α smooth muscle actin (α-SMA) in stress fi  bers, which 
are hallmarks of a differentiated Mf (Tomasek et al., 2002). 
Interfering with α-SMA action by adding a membrane-penetrating 
fusion protein that contains the α-SMA–specifi  c N-terminal se-
quence AcEEED (SMA-FP) signifi  cantly reduces tension genera-
tion by Mfs (Hinz et al., 2002).
Two factors, TGF-β1 and mechanical tension, are pivotal 
in promoting Mf differentiation from a variety of progenitors 
(Hinz et al., 2007). TGF-β1 induces Mf differentiation on two-
dimensional culture substrates with a stiffness that corresponds 
to that of contracting fi  brotic and granulation tissue but not 
on substrates exhibiting the compliance of normal connective 
tissue such as dermis (Goffi  n et al., 2006). TGF-β1 also induces 
Mf differentiation in three-dimensional collagen when gels 
are mechanically restrained (Arora et al., 1999) but not when 
the gels are free-fl  oating and relaxed (Tomasek et al., 2002). 
Conversely, mechanical stress alone fails to induce Mf differen-
tiation in the absence of active TGF-β1, as demonstrated when 
TGF-β1 antagonists are either applied to cells cultured on rigid 
substrates (Arora et al., 1999; Hinz et al., 2001a) or injected into 
stressed granulation tissues (Hinz et al., 2001b). Although it 
is unclear whether and how mechanical stress and TGF-β1 sig-
naling converge to promote increased α-SMA expression and 
Mf differentiation, it is possible that intracellular and extracel-
lular tension directly regulate TGF-β1 activation. Thus, the re-
lease of TGF-β1 from its latent complex by tension would 
produce a signaling molecule that induces Mf differentiation 
and α-SMA expression in a feed-forward manner.
In fi  broblasts and Mfs, TGF-β1 is secreted as part of the 
large latent complex (LLC), which, in addition to TGF-β1, con-
sists of latency associated protein (LAP) and latent TGF-β 
binding protein 1 (LTBP-1). LAP and TGF-β1 form the small 
latent complex (SLC; Miyazono et al., 1991; Annes et al., 2003). 
The LLC provides a reservoir of latent TGF-β1 in the ECM by 
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he conjunctive presence of mechanical stress and 
active transforming growth factor β1 (TGF-β1) is 
essential to convert ﬁ  broblasts into contractile myo-
ﬁ   broblasts, which cause tissue contractures in ﬁ   brotic 
diseases. Using cultured myoﬁ  broblasts and conditions that 
permit tension modulation on the extracellular matrix 
(ECM), we establish that myoﬁ  broblast contraction func-
tions as a mechanism to directly activate TGF-β1 from 
self-generated stores in the ECM. Contraction of myo-
ﬁ   broblasts and myoﬁ   broblast cytoskeletons prepared 
with Triton X-100 releases active TGF-β1 from the ECM. 
This process is inhibited either by antagonizing integrins 
or reducing ECM compliance and is independent from 
protease activity. Stretching myoﬁ  broblast-derived  ECM 
in the presence of mechanically apposing stress ﬁ  bers 
imme  diately activates latent TGF-β1. In myoﬁ  broblast-
populated wounds, activation of the downstream targets 
of TGF-β1 signaling Smad2/3 is higher in stressed com-
pared to relaxed tissues despite similar levels of total 
TGF-β1 and its receptor. We propose activation of TGF-β1 
via integrin-mediated myoﬁ   broblast contraction as a 
potential checkpoint in the progression of ﬁ  brosis, restricting 
autocrine generation of myoﬁ  broblasts to a stiffened ECM.
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binding to other ECM components like fi  brillin-1 and fi  bronec-
tin (FN; Unsold et al., 2001; Annes et al., 2003; Hyytiainen 
et al., 2004; Koli et al., 2005), of which ED-A FN is the major 
splice variant expressed by Mfs (Serini et al., 1998). Several 
cellular mechanisms have been described that activate latent 
TGF-β1 by promoting its dissociation from LAP. These activa-
tion processes include cleavage of LLC by proteases (Mu et al., 
2002; Ge and Greenspan, 2006) such as plasmin as well as in-
teraction of LAP with thrombospondin (for review see Annes 
et al., 2003). Binding of active TGF-β1 to TGF-β receptor type II 
(TGF-β RII) leads to the phosphorylation and recruitment of 
TGF-β RI. This heteromeric receptor complex phosphorylates 
Smad2 and 3, which bind to Smad4 and translocate into the 
nucleus to enhance transcription of Mf-specifi  c genes such as 
α-SMA by cooperating with DNA transcription factors (for review 
see Hinz, 2007).
Recently, the epithelial integrin αvβ6 was demonstrated 
to activate latent TGF-β1 in vivo during development of lung 
fi  brosis (Munger et al., 1998; Jenkins et al., 2006) and in vitro 
(Annes et al., 2004). Because activation by αvβ6 depends on 
incorporation of the TGF-β1 LLC into the ECM via binding 
of the LTBP-1 hinge domain, cell traction mediated by αvβ6 
integrin has been proposed as part of the mechanism of latent 
TGF-β1 activation (Annes et al., 2004; Keski-Oja et al., 2004). 
However, no direct evidence has been provided that mechanical 
stress liberates TGF-β1 from the ECM-bound LLC. In addition, 
although latent TGF-β1 activation by αvβ6 integrin–mediated 
traction can be of physiological signifi  cance during initiation 
of lung and kidney fibrosis where epithelium is prominent 
(Jenkins et al., 2006; Kim et al., 2006), this is unlikely to occur 
during progressive fi  brosis of organs with less abundant epithe-
lium. In such conditions, αvβ6 integrin–negative Mfs are the 
major producers and consumers of TGF-β1.
We show here that both external stretching of Mf cul-
tures and increasing Mf intracellular tension directly activate 
latent TGF-β1 from the ECM. This process requires α-SMA–
positive stress fi  bers and integrin binding to LAP in the LLC. 
Latent TGF-β1 stress activation is limited to culture substrates 
with stiffness similar to that of fi  broblast-populated early wound 
granulation tissue but does not occur on more compliant sub-
strates. We propose that ECM stiffness modulated as a function 
of cell remodeling activity controls the level of TGF-β1 release 
by contraction and thus restricts autocrine maintenance of the 
Mf phenotype to the appropriate mechanical microenvironment.
Results
Mfs activate latent TGF-𝗃1 from 
self-generated stores in the ECM
Autocrine TGF-β1 formation has been suggested as the stimu-
lus for constitutive α-SMA expression in cultured rat lung Mfs 
(Hinz et al., 2001a). To determine whether a portion of this 
TGF-β1 is stored in the ECM as the LLC, we fi  rst assessed 
ECM incorporation of the latent TGF-β1 scaffolding protein 
LTBP-1. Increasing levels of LTBP-1 were incorporated in the 
ECM of lung Mfs over a 7 d period as visualized by immuno-
fl  uorescence (Fig. 1, A–D, green) and confi  rmed by Western 
blotting of plasmin-digested lung Mf ECM (Fig. 1 E). Proteo-
lytic processing was required to liberate LTBP-1 presumably 
because of covalent binding of LTBP-1 to other ECM proteins 
(Nunes et al., 1997). In Mf cultures, LTBP-1 colocalized with the 
Mf-characteristic FN splice variant ED-A FN (Fig. 1, A–D, red), 
that was secreted  1 d earlier as appreciated from the red to 
yellow/green color shift in confocal immunofl  uorescence over 
culture time (Fig. 1, A–D) and from Western blots (Fig. 1 E).
To assess whether the detected LTBP-1 is associated 
with latent TGF-β, we quantifi  ed total TGF-β production after 
activating all latent TGF-β by heating 2–7-d-old Mf cultures 
to 80°C. The heat-released TGF-β was then measured using 
transformed mink lung reporter cells (TMLC), which produce 
luciferase as a function of active TGF-β (Abe et al., 1994). 
To distinguish between cellular and ECM-derived TGF-β, i.e., 
LLC, we fi  rst measured TGF-β in heated trypsinized cells, 
which represent the nonsecreted pool of TGF-β. This fraction 
of total TGF-β was increased as early as 3 d of culture (Fig. 1 F). 
Next, to evaluate only the amount of total TGF-β1 stored in the 
ECM, we removed the cells from cultures with deoxycholate 
(DOC); the effectiveness of extraction was confi  rmed by the 
loss of α-SMA and nuclei in immunofl  uorescence (Fig. 1 D) 
and the loss of vimentin in Western blots (Fig. 1 E). DOC treat-
ment preserved the ECM proteins LTBP-1 and ED-A FN as 
well as LAP (Fig.1 E, DOC). When plasmin-digested ECM 
extracts were blotted under nonreducing conditions, the anti–
LTBP-1 antibody stained two bands (Fig. 1 E). The  240-kD 
band corresponds to LTBP-1 bound to LAP–TGF-β1 and the 
 140-kD band represents unbound LTBP-1 (Koli et al., 2005). 
Consistently, the anti-LAP antibody under nonreducing condi-
tions revealed one band at  240 kD (unpublished data), con-
fi  rming the presence of the LLC in the ECM. Signifi  cant levels 
of TGF-β were liberated by heating Mf-derived ECM to 80°C 
(Fig. 1 F). The response of TMLC to this ECM-derived TGF-β 
was reduced by  90% using function-blocking antibodies against 
TGF-β1, which demonstrates that TGF-β1 is the predominant 
isoform stored in the ECM of Mfs as part of the LLC (Fig. 1 F). 
We will hereafter refer to DOC-extracted, 7-d-old ECM as Mf-
derived ECM, which will be used as a latent TGF-β1–conditioned 
culture substrate.
We next wanted to compare latent TGF-β1 production 
and ECM storage between lung Mfs and rat subcutaneous 
fi  broblasts, which under identical culture conditions express 
low levels of α-SMA (Fig. 1, G and H, left). Fibroblasts exhib-
ited signifi  cantly lower amounts of total TGF-β1 in the cytosol 
(Fig. 1 F, trypsinized cells) and cell-derived ECM (Fig. 1 F) 
compared with Mfs. The ECM from these fi  broblasts also con-
tained lower amounts of LTBP-1 and ED-A FN compared with 
Mfs (Fig. 1, G and H, left). Because fi  broblasts express consid-
erable levels of TGF-β RII (Fig. 1 H, left), it appears that the 
low autocrine production and possibly lower activation of la-
tent TGF-β1 account for low α-SMA expression in these cells. 
Indeed, fi  broblasts expressed α-SMA when treated for 5 d with 
exogenous active TGF-β1 (Fig. 1 H, left). Inversely, lung Mfs 
dedifferentiated into fi  broblasts within 5 d by blocking TGF-β1 
with soluble TGF-β1 RII (Fig. 1 H, left). By these means, 
we produced fi  broblasts and/or Mfs from different precursors.MYOFIBROBLAST CONTRACTION ACTIVATES LATENT TGF-β1 • WIPFF ET AL. 1313
We next evaluated the capacity of contractile Mfs to 
activate latent TGF-β1 from the same Mf-derived ECM com-
pared with low contractile fi  broblasts. Active TGF-β1 produced 
by the cells was quantifi  ed by directly co-culturing TMLC for 
1 d on Mf-derived ECM. Interestingly, Mfs activated more latent 
TGF-β1 than did fi  broblasts (1.5–2-fold) regardless of their 
origin (Fig. 1 H, right). TMLC alone did not activate TGF-β1 
from Mf-derived ECM (unpublished data). The direct contact 
between the experimental and reporter cells was mandatory 
to detect cell-activated TGF-β1, confi  rming previous studies 
demonstrating that nonproteolytically activated TGF-β1 was 
poorly soluble (Munger et al., 1999). To elucidate how much 
of the active TGF-β1 had been liberated from the ECM as op-
posed to secreted, we compared latent TGF-β1 activation from 
Mf-derived ECM to that from cells cultured for the same time 
on tissue culture dishes. On culture dishes, Mfs produced ap-
proximately two- to threefold lower amounts of active TGF-β1 
(Fig. 1 H, right). Collectively, these results demonstrate that 
Mfs not only deposit more latent TGF-β1 in the ECM than 
do fi  broblasts but that Mfs are also more effi  cient in activat-
ing these stores.
Latent TGF-𝗃1 activation from the ECM is 
promoted by Mf contraction
The capacity of fi  broblastic cells to activate latent TGF-β1 
from the ECM (Fig. 1 H, right) correlated with their contractile 
activity (Hinz et al., 2001a). To study further whether contrac-
tion can promote release of TGF-β1 from the ECM, we assessed 
latent TGF-β1 activation after treating Mfs with drugs that 
modulate cell tension development (Fig. S1 and Video 1, avail-
able at http://www.jcb.org/cgi/content/full/jcb.200704042/DC1). 
First, however, we monitored whether these drugs were com-
patible with the TMLC reporter system. When added to TMLC 
alone, Mf contraction agonists thrombin, angiotensin-II (AT-II), 
and endothelin-1 (ET-1), as well as contraction inhibitors cyto-
chalasin D, ML-7, blebbistatin, and SMA-FP did not alter TMLC 
reporter activity in the presence or absence of TGF-β1 (Fig. 2 A). 
In contrast, nocodazole and staurosporin signifi  cantly interfered 
Figure 1.  Mfs activate latent TGF-𝗃1 from self-generated ECM depots. (A–D and G) Lung Mfs were stained for LTBP-1 (green), ED-A FN (red), α-SMA (blue), 
and nuclei (insets) after a 2- (A), 3- (B), or 7-d (C) culture, and after extracting all cellular components with DOC at day 7 (D). (E) Expression of LTBP-1, ED-A FN, 
and α-SMA was further evaluated together with TGF-β RII and LAP by Western blotting; vimentin served as loading control. Whole culture extracts were 
compared with samples taken after both TX-100 (TX; preserves the cytoskeleton and ECM) and DOC (preserves ECM) extraction. LTBP-1 was blotted in non-
reducing conditions after digesting DOC-insoluble ECM overnight with plasmin. (F) Lung Mf (2–7 d) and subcutaneous ﬁ  broblasts (7 d) were examined for 
total TGF-β1. Total TGF-β1 was measured by incubating TMLC with supernatants from 80°C heat-activated trypsinized cells (cellular TGF-β1), as well as 
from heat-activated, DOC-insoluble ECM (ECM-associated total TGF-β1). Function-blocking TGF-β1 antibody was added to test TGF-β isoform speciﬁ  city 
(dashed lines). TGF-β1 concentration was calculated from a standard. (G) Cultures of subcutaneous ﬁ  broblasts were stained after 7 d as in A–D. (H, left) 
Total culture extracts were produced from lung Mfs, lung ﬁ  broblasts (lung F), subcutaneous ﬁ  broblasts (sub F), and subcutaneous Mfs (sub Mf) and blotted 
as in E. Gray lines indicate that intervening lanes have been spliced out. (H, right) The DOC-insoluble fraction of 7-d Mf was used as latent TGF-β1–containing 
ECM for co-culture of ﬁ  broblasts or Mfs with TMLC. TGF-β1 activated by cells during 24 h was measured as luminescence compared with 24-h control 
cultures on plastic culture dishes. Error bars represent the SD of the mean. Bars: (A–D and G) 20 μm; (insets) 200 μm.JCB • VOLUME 179 • NUMBER 6 • 2007  1314
with TMLC luciferase production and were not further con-
sidered (Fig. 2 A). We excluded the possibility that the basal 
luminescence signal of TMLC was caused by TGF-β1 production 
by the reporter cells themselves because addition of a TGF-β1 
function-blocking antibody did not alter basal TMLC reporter 
activity (Fig. 2 A, anti–TGF-β1).
We next tested the effect of these drugs on Mfs. Lung Mfs 
in the presence of thrombin, AT-II, and ET-1 generated 1.6–2-fold 
higher levels of active TGF-β1 (Fig. 2 B, dotted line) when 
compared with the BSA control (broken line). Addition of a 
TGF-β1 function-blocking antibody to nonstimulated Mf/TMLC 
co-cultures reduced luciferase production to  40% of con-
trol (Fig. 2 B, BSA + anti–TGF-β1). When added to Mf in 
the presence of contraction agonist thrombin, AT-II, and ET-1, 
the TGF-β1 function-blocking antibody largely reduced TMLC 
reporter activity (Fig. 2 B), which confi  rms that TGF-β1 is the 
major isoform released upon Mf contraction. It is possible that 
residual luciferase production of TMLC/Mf co-cultured in the 
presence of TGF-β1 antibody is either caused by incomplete 
blocking by the antibody or other cytokines that activate the 
PAI-1 reporter in the TMLC. Consistent with the concept of 
stress-mediated latent TGF-β1 activation, the contraction in-
hibitors cytochalasin D, ML-7, blebbistatin, and SMA-FP de-
creased both thrombin-induced latent TGF-β1 activation (Fig. 2 B, 
+ thrombin) and less strongly basal levels of TGF-β1 activa-
tion (Fig. 2 B). Collectively, these results show that the contrac-
tile activity of Mfs correlates with their capacity to activate 
latent TGF-β1.
Thrombin, the most potent latent TGF-β1–activating ago-
nist in our experiments is also known to liberate active TGF-β1 
from the LLC by proteolytic cleavage at 10-fold higher con-
centrations than used here (0.5 U/ml; Taipale et al., 1992). 
At 0.5 U/ml, thrombin did not release active TGF-β1 from cell-
free, Mf-derived ECM (Fig. 2 C), excluding the contribution of 
proteolysis in contraction-mediated TGF-β1 activation. It was 
only at 10–25-fold higher concentrations (5–25 U/ml) that throm-
bin enzymatically activated latent TGF-β1; plasmin served 
as a positive control (Fig. 2 C; Taipale et al., 1992). To further 
eliminate the role of proteolysis in our system, we stimulated 
Mf contraction in the presence of a protease inhibitor cocktail. 
Stimulating Mf contraction in the presence of protease inhibi-
tors did not interfere with TMLC reporter activity (Fig. 2 D). 
As expected, protease inhibition abolished thrombin-induced 
latent TGF-β1 activation by Mfs (Fig. 2 E) because thrombin 
induces Mf contraction through proteolytic cleavage of the 
protease-activated receptor 1 (Bogatkevich et al., 2003). In con-
trast, when added to Mf/TMLC co-cultures, protease-independent 
contraction of Mfs by ET-1 and AT-II elevated the amounts of 
Figure 2.  Mf contraction activates latent 
TGF-𝗃1. (A) In control experiments, TMLC were 
incubated with various drugs for 1 h in the 
presence (dashed bars) or absence (solid bars) 
of TGF-β1. The TGF-β1 function-blocking anti-
body was used to assess the contribution of 
this isoform to the baseline luciferase level in 
TMLC cultures. (B) The role of Mf contraction in 
activating latent TGF-β1 was tested by seeding 
TMLC directly on 7-d-old Mf cultures 4 h before 
the addition of contraction-promoting drugs. 
An anti–TGF-β1 antibody was used to test 
TGF-β1 contribution in the luciferase response 
in Mf/TMLC co-cultures. Cell contraction inhib-
itors were added to contraction-stimulated and 
control cultures. The dotted line indicates the 
level of latent TGF-β1 activation by the most 
potent contraction agonist thrombin; the bro-
ken line shows baseline latent TGF-β activation 
by Mfs. Results are expressed as the percent-
age of nonstimulated control (BSA) corrected 
for TMLC baseline reporter activity. (C) To con-
trol whether contraction agonists alone activate 
latent TGF-β1 from the ECM, lung Mf-derived 
ECM was treated for 1 h with thrombin and 
active TGF-β1 release into the supernatant 
was assessed with TMLC; ECM digested with 
plasmin for 1 h was used as a positive control. 
(D) TMLC were incubated with protease inhibi-
tors together with contractile drugs for 1 h in 
the presence or absence of TGF-β1 to control 
interference with reporter activity. (E) Protease 
inhibitor cocktail was added simultaneously with 
contraction-promoting drugs to test whether pro-
teases are involved in latent TGF-β1 activation 
by Mf contraction. Error bars represent the SD 
of the mean.MYOFIBROBLAST CONTRACTION ACTIVATES LATENT TGF-β1 • WIPFF ET AL. 1315
active TGF- β1 by 1.8–2.5-fold compared with the BSA control 
in the presence of protease inhibitors (Fig. 2 E, dotted line). 
These results demonstrate that Mf contraction directly activates 
latent TGF-β1 in a protease-independent mechanism.
Contraction activation of latent TGF-𝗃1 
from the ECM is integrin mediated
The fi  broblast integrins that bind to the LLC and are poten-
tially involved in protease-independent latent TGF-β1 activa-
tion are αvβ3, α8β1, and αvβ5 (Levine et al., 2000; Lu et al., 
2002; Mu et al., 2002; Ludbrook et al., 2003; Asano et al., 2005; 
Sheppard, 2005; Araya et al., 2006). As visualized by immuno-
fl  uorescence, cultured lung Mfs do express β3 (Fig. 3 A) and β1 
(Fig. 3 B) integrin subunits and αvβ5 integrin (Fig. 3 C). Τo in-
vestigate whether activation of latent TGF-β1 by Mf contrac-
tion was mediated by integrin binding to the LLC, we added 
integrin effectors to nonstimulated and thrombin-contraction–
stimulated Mf/TMLC co-cultures (Fig. 3 D). Basal (broken line) 
and contraction-induced activation of latent TGF-β1 (dotted 
line) were strongly increased by the integrin activator Mn
2+ 
(Fig. 3 D). In contrast, general integrin blocking with RGD pep-
tides and specifi  c inhibition of integrin binding to LAP in the 
LLC with a competitive LAP–TGF-β1 (LAPβ1) decapeptide 
inhibited basal and thrombin-induced activation of latent TGF-β1 
(Fig. 3 D). Comparable results were obtained with exogenously 
added soluble SCL that competes with LTBP-bound SLC (un-
published data). Soluble SLC, however, severely increases the 
reporter activity of TMLC alone and was excluded here. At the 
concentration used, the RGD-containing peptides did not alter 
cell spreading or stress fi  ber formation (Fig. S2, available at 
http://www.jcb.org/cgi/content/full/jcb.200704042/DC1). Control 
DGR peptides had no effect (Fig. 3 E).
To identify the integrins involved in latent TGF-β1 activa-
tion by Mf contraction, we applied specifi  c function-blocking 
antibodies. Addition of anti-αvβ5 strongly reduced both basal 
and contraction-induced latent TGF-β1 activation, whereas 
anti–β1 and –β3 integrin function-blocking antibodies only 
mildly inhibited latent TGF-β1 activation in both conditions 
(Fig. 3 D). All effectors were also tested on TLMC reporter 
activity in the absence of Mfs (Fig. 3 E). Together, these results 
demonstrate that integrin binding to LAP is required to activate 
latent TGF-β1 from the LLC and αvβ5 integrin is predominantly 
involved in latent TGF-β1 activation by Mf contraction.
Stress activation of latent TGF-𝗃1 requires 
the Mf cytoskeleton
Protease inhibition reduced activation of latent TGF-β1 in Mf 
cultures by  40%, which suggests that proteolysis is part of 
basal latent TGF-β1 activation (Fig. 2 G). To exclude a role 
for proteases in integrin-mediated latent TGF-β1 activation by 
Figure 3.  Activation of latent TGF-𝗃1 by Mf contraction is integrin mediated. Cultured rat lung Mfs express β3 (A), β1 (B), and αvβ5 integrin (C), as shown 
by confocal micrographs produced from immunostaining. (D) TMLC were seeded directly on 7-d-old Mf cultures 2 h before adding modulators of inte-
grin binding for an additional 2 h; this was followed by another 1-h incubation in the absence or presence of 0.5 U/ml thrombin. Integrin binding 
was stimulated with Mn
2+ and inhibited using RGD peptides, LAP–TGF-β1 (LAPβ1) decapeptide, and integrin function-blocking antibodies; scrambled 
DGR peptide was used as control. The broken line shows basal latent TGF-β1 activation by Mfs; the dotted line demonstrates active TGF-β1 levels after 
inducing contraction with thrombin only. Results are expressed as a percentage of nonstimulated control (BSA) corrected for TMLC baseline reporter activity. 
(E) Controls were performed to test the effect of integrin modulators on TMLC reporter activity with and without stimulation by TGF-β1 and 0.5 U/ml thrombin. 
Error bars represent the SD of the mean. Bar, 10 μm.JCB • VOLUME 179 • NUMBER 6 • 2007  1316
Mf contraction, we extracted 7-d cultures of Mfs with Triton 
X-100 (TX-100). This treatment preserved the ECM, the α-SMA 
and vimentin cytoskeleton (Fig. 1 E), and focal adhesion integ-
rity (Hinz et al., 2003). Cytosol and membranes were com-
pletely removed as shown by the loss of the membrane marker 
Na
+/K
+-ATPase (Fig. 4 A). Addition of ATP to such TX-100 
cytoskeletons induced dramatic contraction of stress fi  bers (Fig. 4, 
B and C; and Video 2, available at http://www.jcb.org/cgi/
content/full/jcb.200704042/DC1) clearly visualized by kymo-
graphic analysis over a line positioned along the extracted cell’s 
axis and the substrate (Fig. 4 D). ATP-induced contraction in-
creased active TGF-β1 by 4.5-fold compared with nonstimu-
lated cytoskeletons in the presence and absence of protease 
inhibitors (Fig. 4 E). Latent TGF-β1 activation by ATP-induced 
contraction was reduced to approximately threefold upon incu-
bation with either the LAP–TGF-β1 decapeptide or the anti-β1 
or -β3 integrin antibodies and reduced to  1.5-fold upon incu-
bation with the anti-αvβ5 integrin antibody; these inhibitors 
had little effect on basal TGF-β1 activity in the absence of ATP 
(Fig. 4 E). ATP did not activate latent TGF-β1 from Mf-derived 
ECM (unpublished data) and did not interfere with TMLC reporter 
activity (Fig. 4 F). Together, these data show that Mf contraction, 
mediated by β1, β3, and most strongly by αvβ5 integrin binding to 
LAP, directly activates latent TGF-β1 from the LLC by a protease-
independent mechanism.
To directly test activation of latent TGF-β1 by mechanical 
forces, we subjected Mf cultures on stretchable silicone membranes 
to unique stretches of up to 10%. We fi  rst controlled whether 
stretching interfered with TMLC reporter activity (Fig. 5 A). 
When TMLC were grown directly on the silicone membrane, 
10% stretching did not affect baseline reporter activity but attenu-
ated the response to TGF-β1 (Fig. 5 A). To accomplish the nec-
essary close contact with lung Mfs and simultaneously protect 
the TMLC from stretching, we developed the “TMLC sandwich” 
assay (Fig. 5 B). In this assay, TMLC grown on glass coverslips 
were placed upside-down on top of Mfs during stretching and 
removed shortly after (1 min) for separate analysis of luciferase 
production (Fig. 5 B). Control experiments without Mfs demon-
strated no interference of the TMLC response to TGF-β1 in this 
confi  guration (Fig. 5 A).
Stretching Mfs by 3% increased active TGF-β1 by threefold 
compared with controls (Fig. 5 C). No signifi  cant further augmen-
tation of active TGF-β1 levels was observed at higher stretches 
(Fig. 5 C). Stretch-activated TGF-β1 exerted a stimulatory re-
sponse on Mf differentiation as demonstrated by enrichment of 
phosphorylated Smad2 in the nuclei of Mfs within 1 h after 
stretching (Fig. 5, E–G), which indicates that TGF-β1 binds to 
its receptor (Heldin et al., 1997). This was confi  rmed by Western 
blotting, demonstrating increased Smad2/3 phosphorylation at 
unchanged levels of total Smad2/3 (Fig. 5, H and I).
To investigate whether the Mf cytoskeleton is required for 
activation of latent TGF-β1 by stretching, we preextracted Mfs 
with TX-100 or DOC (Fig. 5 D). In Mf cytoskeletons, 3% 
stretching increased active TGF-β1 in the supernatant by fi  vefold 
compared with nonstretched controls (Fig. 5 D, TX-100). In con-
trast, stretch failed to activate latent TGF-β1 from Mf-derived 
ECM after treatment with DOC (Fig. 5 D, DOC). Subsequent 
heat activation of stretched Mf-derived ECM to 80°C always 
confi  rmed the presence of ECM-bound latent TGF-β1 after DOC 
extraction (unpublished data). Hence, mechanical activation of 
Figure 4.  Integrin-transmitted contraction of 
TX-100 cytoskeletons activates latent TGF-𝗃1. Cyto-
skeletons from 7-d-old Mf cultures were produced 
by cell extraction with TX-100. (A) Extraction efﬁ  -
ciency was monitored by Western blotting for 
the plasma membrane–associated Na
+/K
+-ATPase. 
Stress ﬁ  bers remaining after TX-100 extraction (B) 
were contracted by adding ATP for 30 min (C). 
Kymograph lines, 150 μm. Bar, 25 μm. (D) Isolated 
stress ﬁ  ber contraction was visualized by a kymo-
graph produced along the overlaid white lines in 
A and B. (E) TX-100 cytoskeletons were incubated 
for 2 h with protease inhibitors and integrin antag-
onists and subsequently contracted with ATP for 1 
h; supernatants were analyzed for their content in 
active TGF-β1. Results are expressed as the per-
centage of nonstimulated control (BSA) corrected 
for TMLC baseline reporter activity. (F) To control 
for the inﬂ  uence of ATP on TMLC reporter activity, 
TMLC were incubated with ATP for 1 h in the pres-
ence (dashed bars) or absence (solid bars) of TGF-
β1. Error bars represent the SD of the mean.MYOFIBROBLAST CONTRACTION ACTIVATES LATENT TGF-β1 • WIPFF ET AL. 1317
TGF-β1 from the ECM requires the resistance of functional 
stress fi  bers.
Activation of latent TGF-𝗃1 by Mf 
contraction requires mechano-resistant ECM
Mf differentiation and function depend on a threshold of ECM 
stiffness (Arora et al., 1999; Goffi  n et al., 2006). To investigate 
whether the mechanical properties of the ECM modulate the 
level of contraction-activated latent TGF-β1, we assessed latent 
TGF-β1 activation by Mfs grown on silicone culture substrates 
with tunable Young’s modulus (5–47 kPa) in direct co-culture 
with TMLC (Fig. 6 A). Basal TGF-β1 activation increased by 
 1.5-fold between 5-kPa soft substrates that mimic the compli-
ance of a normal dermis and substrates exhibiting a stiffness 
corresponding to that of fi  brotic and late wound granulation tis-
sue (47 kPa; Goffi  n et al., 2006). Induction of Mf contraction 
with thrombin enhanced latent TGF-β1 activation on 9–47-kPa 
substrates by approximately twofold but had no effect on 5-kPa 
soft substrates (Fig. 6 A). Substrate compliance only mildly 
reduced total TGF-β1 production as assessed by heating Mf-
derived ECM to 80°C (Fig. 6 B). Cell numbers were comparable 
in all conditions and TMLC controls produced similar levels 
of luciferase on all substrates (unpublished data).
These results suggest that activation of latent TGF-β1 by 
Mf contraction requires a threshold ECM resistance. However, 
we have previously shown that incorporation of α-SMA into 
contractile stress fi  bers of rat embryonic fi  broblasts is impaired 
by prolonged growth on soft substrates (Goffi  n et al., 2006), 
which is also observed for lung Mfs (Fig. 6, C–E). In contrast, 
after 8 h in culture, α-SMA expression and incorporation into 
lung Mf stress fi  bers was comparable between 5-kPa soft (Fig. 6, 
C and F) and 47-kPa stiff substrates (Fig. 6 C, incorporation 
similar to E). To obtain both suffi  cient amounts of ECM-stored 
TGF-β1 and cells incorporating α-SMA into stress fi  bers, Mfs 
were fi  rst precultured for 7 d on silicone substrates and then 
extracted with DOC. Next, fresh Mfs were seeded onto the Mf-
derived ECM for 8 h and latent TGF-β1 activation was assessed. 
Substrate compliance did not alter LTBP-1 expression, as shown 
by confocal immunofl  uorescence (Fig. 6, G and H), and did not 
change total TGF-β1 in the ECM (Fig. 6 B). Importantly, even 
under these conditions that preserved α-SMA–positive stress 
fi  bers, activation of latent TGF-β1 by thrombin-induced Mf con-
traction was reduced on soft versus stiffer substrates (Fig. 6 I). 
Thus, to promote activation of latent TGF-β1 by Mf contrac-
tion, the LLC needs to be part of an ECM that resists the cell-
generated mechanical stress.
Stretching of LTBP-1 ﬁ  bers by Mf 
contraction is reduced on compliant ECM
To analyze how substrate compliance affects LLC fi  ber organi-
zation during Mf contraction, we compared the dynamics of 
fl  uorescently labeled LTBP-1 between 5-kPa soft (Fig. 7, A, B, 
and E) and 47-kPa stiff (Fig. 7, C, D, and F) substrates. For this 
experiment, Mfs were cultured for 8 h on Mf-derived ECM. 
On soft ECM that provided little resistance against cell contrac-
tion, we noted signifi  cant displacement of LTBP-1 toward the 
center of Mfs upon contraction with thrombin (Fig. 7, A and B; 
and Video 3, available at http://www.jcb.org/cgi/content/full/
jcb.200704042/DC1). Displacement is visualized by overlaying 
LTBP-1 position before (Fig. 7, green) and 1 h after stimulation of 
Mf contraction (red). Individual fi  ber aggregates were shortened 
Figure 5. Latent  TGF-𝗃1 activation by mechanical stress requires a func-
tional cytoskeleton. (A) To control whether stretching interferes with TGF-β1 
reporting activity, TMLC were directly grown on a silicon membrane and 
stretched by 10% in the presence and absence of 10 pM TGF-β1. Reporter 
activity was compared with TMLC grown on coverslips to protect from 
stretching and placed upside-down on the membrane during 10% stretch-
ing. (B) This conﬁ  guration was repeated in the sandwich assay, in which 
lung Mfs were cultured for 7 d on silicone membranes that were stretched 
3–10%. After stretching, TMLC were cultured separately for further analysis. 
Active TGF-β1 was measured as a function of stretch applied to TMLC/Mf 
sandwich cultures (C), TX-100 cytoskeletons, and Mf-derived ECM (DOC; D). 
Active TGF-β1 is expressed as the percentage of nonstretched control (con) 
corrected for TMLC baseline reporter activity. Phosphorylation of Smad2 
(pSmad2) was assessed by immunoﬂ  uorescence detecting pSmad2 in 
nonstretched (E) and 10% stretched (F) conditions and by Western blotting of 
Mf culture extracts equilibrated for total Smad2 (H). Intensity of pSmad2 
labeling in the nuclei (G) and of pSmad2 bands on the Western blot (I) was 
quantiﬁ  ed by densitometric analysis. Error bars represent SD of the mean. 
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by compression and bending (Fig. 7 E and Video 4). In contrast, 
on mechanically resisting ECM, little displacement was ob-
served for the bulk ECM (Fig. 7, C and D; and Video 5). Here, 
LTBP-1 localization before and after cell contraction exhibited 
high overlap (Fig. 7 A, yellow). However, locally, individual fi  bers 
underwent signifi  cant straightening (Fig. 7 F), sometimes even 
leading to fi  ber rupture (Video 6). We concluded that contraction-
mediated stretching of individual fi  bers against a mechano-
resistant ECM anchor liberates TGF-β1.
Releasing rat wounds from mechanical 
tension decreases phosphorylation of 
Smad2/3
Finally, we evaluated the expression of Mf markers and compo-
nents of the TGF-β1 signaling cascade in rat wound granulation 
tissue subjected to different levels of stress. In normally healing 
control wounds, α-SMA was neoexpressed by 9 d after wound-
ing (Fig. S3 A, available at http://www.jcb.org/cgi/content/full/
jcb.200704042/DC1). Expression of α-SMA was induced earlier 
and stronger by 6 d and enhanced after 9 d after wounding, 
when wounds were subjected to mechanical stress by splinting the 
edges with a plastic frame as described previously (Hinz et al., 
2001b). Relaxation of prestressed wounds by removing the splint 
after 8 d for 2 d signifi  cantly reduced α-SMA expression levels 
compared with 10-d stressed wounds (Fig. S3 A). Expression of 
α-SMA correlated with the activation state of Smad2 and 3 in 
granulation tissue; phosphorylation of Smad3 and more signifi  -
cantly Smad2 was increased by stress and decreased by wound 
relaxation. However, expression of TGF-β1 RII, total Smad2, 
Smad3, and LAP was not altered by stress (Fig. S3 A). Similarly, 
total levels of TGF-β1 in the granulation tissue were similar 
between control (Fig. S3, A and B) and stressed wounds after 6 
(Fig. S3, A and compare B to C) and 9 d (Fig. S3 A) and 
between 10-d stress-relaxed (Fig. S3A, D) and 10-d stressed 
wounds (Fig. S3, A and compare D to E). In all conditions, 
reepithelialization was negligible (Fig. S3, B–E). This result 
indicates that stress induces higher activity of TGF-β1 in the 
granulation tissue in the absence of a prominent epithelium 
(i.e., αvβ6-expressing cells) without signifi  cantly altering latent 
TGF-β1 expression levels.
Discussion
Mechanical tension in conjunction with the presence of ac-
tive TGF-β1 is a prerequisite for the development of α-SMA–
 positive  fi  brogenic Mfs (Arora et al., 1999; Hinz et al., 2001b). 
However, a direct link between both factors has not been estab-
lished. Here, we provide evidence that Mfs activate TGF-β1 from 
Figure 6.  Activation of latent TGF-𝗃1 by Mf contraction 
increases with increasing ECM stiffness. (A) Lung Mfs were 
cultured for 7 d on silicone substrates with increasing stiffness 
(Young’s modulus). TMLC reporter cells were added for a 4-h 
direct co-culture to assess active TGF-β1 with and without pro-
moting Mf contraction using 0.5 U/ml thrombin. (B) Total TGF-
β1 content was measured in the supernatant of heat-activated 
DOC-insoluble ECM produced from each substrate condition; 
values are expressed as luminescence in the TMLC reporter 
system. (C) Protein expression was evaluated by Western blot-
ting normalized for vimentin expression and by immunostain-
ing (D–F) for α-SMA (red), F-actin (green, phalloidin), and 
nuclei (blue) after 7 (D and E) and 8 h (F) of culture on 5-kPa 
compliant (D and F) and 47-kPa stiff (E) substrates. ECM was 
extracted with DOC from 7-d Mf cultures on compliant (G) 
and stiff (H) substrates and immunostained for LTBP-1. (I) Mfs 
were freshly seeded onto Mf-derived, DOC-insoluble ECM 
and cell-activated TGF-β1 was evaluated after 8 h of direct 
co-culture with TMLC as luminescence. Error bars represent 
the SD of the mean. Bar, 100 μm.MYOFIBROBLAST CONTRACTION ACTIVATES LATENT TGF-β1 • WIPFF ET AL. 1319
self-generated and predeposited ECM stores by a contraction-
mediated mechanism. Three elements are mandatory to liberate 
TGF-β1 from this ECM: (1) high contractile activity generated by 
α-SMA–positive stress fi  bers; (2) stress transmission to LAP–TGF-
β1 via integrins; and (3) integration of the LLC into a mechano-
resistant ECM (Fig. 8). We propose that tension-mediated activation 
of TGF-β1 plays an important role in maintaining Mf differen-
tiation in mechanically challenged environments, e.g., in the stiff 
ECM of fi  brotic lesions (Hinz, 2007), during the contraction 
phase of wound healing (Goffi  n et al., 2006) and in the stiff 
stroma that surrounds epithelial tumors (Paszek and Weaver, 2004; 
Amatangelo et al., 2005).
Several new fi  ndings establish Mf contraction as a novel 
mechanism to directly activate latent TGF-β1 from the ECM. 
Stimulation of Mf contraction with AT-II, ET-1, and thrombin 
increases the level of active TGF-β1 independently from prote-
ase activity. Thrombin was recently shown to enhance TGF-β1 
activation by epithelial cells in an αvβ6 integrin–dependent 
manner, presumably via the receptor protease-activated receptor 1 
and downstream activation of RhoA ( Jenkins et al., 2006). More-
over, adenoviral infection with a constitutively active form of RhoA, 
which is known to enhance actin reorganization, leads to increased 
TGF-β activation in β6 integrin–transfected fi  broblasts (Jenkins 
et al., 2006). It has been suggested that subsequent cytoskeletal 
changes enhance cell traction without further evaluating this point 
(Jenkins et al., 2006). We reduced the activation of latent TGF-β1 
by inhibiting Mf contractile activity generated in α-SMA–positive 
stress fi  bers. Low contractile fi  broblasts were consistently less effi  -
cient in liberating active TGF-β1 from Mf-derived ECM com-
pared with their α-SMA–positive counterparts. ATP-induced 
contraction of TX-100 cytoskeletons alone is suffi  cient to re-
lease active TGF-β1 from Mf-derived ECM independently from 
membrane-located secreted factors or proteases. Extracellular 
stress applied to Mfs and TX-100 cytoskeletons almost instantly 
liberates active TGF-β1 from the ECM, which indicates that 
neither synthesis nor secretion of TGF-β1 are involved.
Figure 7.  Stretching of LTBP-1 ﬁ   bers by Mf contraction is reduced on 
compliant ECM. Mfs were grown for 8 h on 5-kPa soft (A, B, and E) and 
47-kPa stiff (C, D, and F) silicone substrates provided with 7-d Mf-derived 
ECM. Living Mfs were incubated for 2 h with ﬂ  uorescently labeled LTBP-1 
antibody to follow LTBP-1 displacement by videomicroscopy. The image 
ﬁ  eld includes the ECM associated with one cell. Displacement is visualized 
by overlaying initial LTBP-1 position (green) with LTBP-1 images taken 1 h 
after stimulating Mf contraction (red) with 0.5 U/ml thrombin. Dynamic 
deformation over 1 h was analyzed from Videos 3 and 5 (available at 
http://www.jcb.org/cgi/content/full/jcb.200704042/DC1) using kymo-
graphs (B and D) extracted along the white lines that span the long axis of 
one cell. Kymograph lines, 200 μm. Dotted lines on kymographs indicate 
ﬁ  ber displacement toward the cell center on soft and rather static overall 
behavior on stiff substrates. Close-up frames taken every 12 min from 
selected ﬁ  bers demonstrate ﬁ  ber compression on soft (E, diagonal scale 
bars indicate the shortening of the ﬁ  ber; Video 4) and stretching on stiff 
substrates (F, dotted line; Video 6). Bars, 25 μm.JCB • VOLUME 179 • NUMBER 6 • 2007  1320
One of our major fi  ndings is that the effi  ciency of latent 
TGF-β1 activation by Mf contraction increases with increasing 
ECM stiffness. We suggest that the transmission of Mf force to 
the LLC induces a conformational change in LAP that liberates 
active TGF-β1 (Fig. 8), which is similar to a recent model pro-
posed for epithelial cells (Annes et al., 2003). Whereas compliant 
substrates appear to absorb the large deformations generated by 
Mf contraction and thus protect the LLC against conformational 
changes (Fig. 7 A), individual fi  bers become stretched on stiff 
substrates. In our experiments, stretching the ECM by 3–10% 
liberates active TGF-β1 from the LLC in the presence of the 
mechanically resistant Mf cytoskeleton; this stretch is in the 
same range as what has been described to reveal cryptic self-
assembly sites in FN (Zhong et al., 1998) and to mediate mechano-
transduction by various extracellular and cytoplasmic proteins 
(Giannone and Sheetz, 2006; Vogel, 2006). To allow deformation 
by cell traction, the LLC must be connected to an element that 
provides resistance to mechanical strain (Annes et al., 2004; 
Keski-Oja et al., 2004). Consistent with this idea, transformed 
fi  broblasts overexpressing SLC (LAP–TGF-β1) do not induce 
Mf formation when implanted into mouse dermis (Campaner et al., 
2006), presumably because of the lack of ECM fi  xation in the 
absence of LTBP-1.
The necessity for anchoring LTBP-1 with a resistant ECM 
offers the intriguing possibility that the level of ECM remodeling 
controls the availability of active TGF-β, e.g., during the course of 
wound healing. Normal dermis contains significant levels of 
LTBP-1 that potentially acts as a repository for the TGF-β1 
LLC (Karonen et al., 1997; Raghunath et al., 1998), and the 
levels of total TGF-β1 are elevated during all stages of wound 
healing (Brunner and Blakytny, 2004). In contrast, active TGF-β1 
is generally low and peaks during early infl  ammation as well as 
during the phase of wound contraction by Mfs (Yang et al., 1999). 
The question arises why α-SMA–negative fi  broblasts, which 
are abundant during early wound remodeling, are not capable 
of activating existing latent TGF-β1 deposits from the ECM. 
Our in vivo data suggest that ECM stress makes the difference; 
wound granulation tissue between 6 and 10 d after wounding 
exhibits signifi  cantly higher activation of the TGF-β1 downstream 
targets Smad2/3 and higher expression of α-SMA in stressed com-
pared with relaxed wounds, which indicates enhanced TGF-β1 
signaling. This is achieved with similar levels of total TGF-β1. 
It remains to be investigated whether our concept of high Mf 
contraction and high ECM tension is applicable to αvβ6-mediated 
latent TGF-β1 activation that occurs with the low traction force 
generated by cultured epithelial cells. The fact that αvβ6-mediated 
latent TGF-β1 activation in an animal model of early lung fi  brosis 
is augmented by high-tidal-volume ventilation, i.e., stress (Jenkins 
et al., 2006), seems to support the requirement for a mechanically 
loaded ECM in this system.
Stretching Mf-derived stiff ECM only liberated active 
TGF-β1 in the presence of the Mf cytoskeleton in our experi-
ments, and depolymerization of the actin cytoskeleton com-
pletely blocked activation of latent TGF-β1 by epithelial cells 
(Munger et al., 1999). These results indicate that the proposed 
LLC conformation change requires a second, cellular anchor 
point. We show that integrin binding to LAP in the LLC is es-
sential for the contraction-mediated activation process because 
RGD peptide competitors and the LAP–TGF-β1 decapeptide 
decrease contraction-mediated activation of TGF-β1. We can 
exclude integrin binding to other RGD sequences in the LTBP-1 
because these epitopes are not present in the rat LTBP-1. Integrins 
αvβ5, β3, β1, and β8 are expressed in fi  broblastic cells and 
bind to RGD in LAP (Levine et al., 2000; Lu et al., 2002; Mu 
et al., 2002; Ludbrook et al., 2003; Asano et al., 2005; Sheppard, 
2005; Araya et al., 2006). Activation of latent TGF-β1 by binding 
of αvβ8 integrin to SLC involves proteolytic action of MT1–
matrix metalloproteinase and does not require incorporation of 
LLC into the ECM (Mu et al., 2002). The generally low levels 
of active TGF-β1 in the culture supernatant and the activation 
of latent TGF-β1 by purifi  ed cytoskeletons all rule out αvβ8 
integrin–assisted proteolytic release in our conditions.
In contrast to αvβ8, integrins αvβ5 and β3 are interesting 
candidates for latent TGF-β1 stress activation because they are 
involved in TGF-β1 activation by systemic sclerosis fi  broblasts 
and their inhibition reverses the myofi  broblastic phenotype by a 
yet undefi  ned mechanism (Scaffi  di et al., 2004; Asano et al., 
2005, 2006). Function blocking of the β3 integrin in our hands 
moderately reduces latent TGF-β1 activation by Mf contraction. 
On the contrary, inhibition of αvβ5 integrin signifi  cantly reduces 
contraction-mediated latent TGF-β1 activation by Mfs and TX-
100 cytoskeletons, which suggests that αvβ5 integrin predomi-
nantly mediates stress activation of latent TGF-β1 in Mfs.
Figure 8.  Model of Mf contraction-mediated TGF-𝗃1 activation. The high 
contractile activity generated by α-SMA in stress ﬁ  bers is transmitted at 
sites of integrins binding to RGD sites in the LAP protein as part of the 
LLC, which also includes TGF-β1 and LTBP-1. (A) When the LLC is anchored 
in a comparably stiff ECM, cell-mediated stress can induce allosteric 
changes in LTBP-1 and/or LAP conformation, leading to liberation of 
TGF-β1; such activated TGF-β1 possibly feeds back by binding to its 
receptor, which is located close by in the activating cell. (B) In the context 
of compliant ECM, the LLC is dragged toward the pulling cell but be-
cause of the lack of mechanical resistance, no conformation change occurs 
and TGF-β1 remains latent. Likewise, inhibition of high cell contraction 
and interaction of integrins with the LLC block mechanical activation of 
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Notably, by blocking β1 integrin in Mfs and TX-100 cyto-
skeletons, we also inhibit latent TGF-β1 activation in the presence 
of contraction agonists. Integrin α8β1 was previously shown to 
strongly interact with LAP–TGF-β1 (Lu et al., 2002) and is 
up-regulated in conjunction with Mf differentiation during heart 
(Bouzeghrane et al., 2004), pulmonary, and hepatic fi  brosis 
(Levine et al., 2000). However, overexpression of α8β1 integrin 
in nonfi  broblastic cells does not enhance levels of active TGF-β1 
(Lu et al., 2002). This apparent discrepancy with our results can 
be explained by the low contractile potential of the transfected 
cells or by the involvement of another β1 integrin heterodimer 
that has not yet been shown to bind to LAP. Further studies along 
this line shall identify this candidate for contraction-mediated 
latent TGF-β1 activation and elucidate its respective contribution 
compared with αvβ5 integrin.
Until now, activation of latent TGF-β1 by cell traction has 
been suggested exclusively for the epithelial integrin αvβ6 
(Annes et al., 2004; Yang et al., 2007), which is involved in the 
initiation of lung fi  brosis (Jenkins et al., 2006; Munger et al., 
1999). During fi  brosis of epithelialized tissues, such as kidney 
and lung, Mfs are partly recruited through mesenchymal transition 
of epithelial cells (Hinz et al., 2007) involving αvβ6 integrin–
mediated latent TGF-β1 activation (Kim et al., 2006). However, 
the evolution of pulmonary fi  brosis toward end-stage fi  brotic 
lung disease depends on the persistence of αvβ6-negative Mfs 
to express and activate latent TGF-β1 (Phan, 2002; Thannickal 
et al., 2004). Furthermore, Mfs drive fi  brosis in a variety of other 
organs that neither exhibit a pronounced epithelium nor posses 
cells expressing αvβ6 integrin (Hinz et al., 2007). Our data 
strongly suggest that in these conditions, Mfs liberate and activate 
TGF-β1 from preexisting and self-generated deposits in the ECM 
by transmitting their high contractile force to the LLC through 
αvβ5 integrin and yet unidentifi  ed β1 and 3 integrins.
Materials and methods
Cell culture and reagents
Primary rat lung Mfs expressing constitutively high levels of α-SMA and 
low α-SMA–expressing subcutaneous ﬁ  broblasts were isolated and cul-
tured as described previously (Hinz et al., 2001a). Subcutaneous Mf 
differentiation was induced with 5 ng/ml TGF-β1 (R&D Systems) for 5 d; to 
dedifferentiate lung Mfs, we applied 250 ng/ml of recombinant soluble 
TGF-β RII (provided by V. Koteliansky, Alnylam Pharmaceuticals, Cambridge, 
MA) for 5 d. Anti–TGF-β1 antibody (chicken, AF-101-NA; R&D Systems) 
was used to neutralize TGF-β1 activity (10 μg/ml). Contraction was in-
duced with 0.5 U/ml thrombin, 100 μM ET-1, 5 μg/ml nocodazole, 10 μM 
AT-II, and 100 mM ATP (all obtained from Sigma-Aldrich). To inhibit 
contraction, we used 3 μg/ml of the Mf-speciﬁ  c SMA-FP (provided by 
C. Chaponnier, University of Geneva, Geneva, Switzerland), 100 μM 
blebbistatin (EMD), 10 μM cytochalasin D, and 50 nM staurosporin 
(both obtained from Sigma-Aldrich). Integrin binding was stimulated with 
500 μM Mn
2+ and antagonized using 100–500 mM RGD peptides (RGDS 
and control SDGR; Sigma-Aldrich). Function-blocking antibodies against 
β1 integrin (rabbit, AB1937; Millipore), β3 integrin (mouse clone F11; 
BD Biosciences), and αvβ5 integrin (mouse clone P1F6; Abcam) were 
added at 10 μg/ml for 3 h. Integrin binding to LAP was inhibited with 
100 μg/ml of a custom-synthesized decapeptide containing the RGD 
sequence and ﬂ  anking amino acids of rat LAP (K  R  R  G  D  L  S  T  I  H  ). Protease 
activity was blocked with an inhibitor cocktail (Roche) plus 1 mM PMSF and 
1 mM TAME.
Antibodies and microscopy
For immunoﬂ  uorescence and Western blotting we used primary antibod-
ies against α-SMA (mouse IgG2a and α-SM-1; provided by G. Gabbiani, 
University of Geneva; Skalli et al., 1986), LAP (goat, AF-246-NA; R&D 
Systems), LTBP-1 (rabbit, Ab39; provided by C.-H. Heldin, University of 
Uppsala, Uppsala, Sweden; Kanzaki et al., 1990), ED-A FN (mouse 
IgG1, IST-9; provided by L. Zardi, National Institute for Cancer Research, 
Genoa, Italy; Serini et al., 1998), TGF-β RII (rabbit, L-21; Santa Cruz 
Biotechnology, Inc.), vimentin (mouse IgG1, V9; Dako), vinculin (mouse 
IgG1, hVin-1; Sigma-Aldrich), phosphorylated and total Smad2 and 3 
(Cell Signaling Technology), anti–Na
+/K
+-ATPase (mouse clone α6F), 
and anti-integrin antibodies (see Cell culture and reagents). For immuno-
ﬂ  uorescence, antibodies against integrins and LTBP-1 were added for 1 h 
to living cells before ﬁ  xation; all other primary antibodies were added 
after cell ﬁ  xation and permeabilization and probed with TRITC- and FITC-
conjugated goat anti–mouse IgG2a (SouthernBiotech) and Alexa Fluor 
488–conjugated goat anti–rabbit secondary antibodies (Invitrogen). 
DNA was detected with DAPI (Sigma-Aldrich) and F-actin was detected 
with phalloidin–Alexa 488 (Invitrogen). For Western blotting, we used 
HRP-conjugated secondary antibodies goat anti–mouse and goat anti–
rabbit (Jackson ImmunoResearch Laboratories). LTBP-1 was digested from 
DOC-extracted and scraped ECM using 0.05 U/ml of human plasma 
plasmin (Sigma-Aldrich) overnight at 37°C and resuspended in nonreducing 
sample buffer.
Live microscopy was performed in F12/10% FCS with an oil immersion 
objective (Plan-Neoﬂ  uar 63× 1.4 Ph3; Carl Zeiss, Inc.) mounted on an 
inverted microscope (Axiovert 135; Carl Zeiss, Inc.) with a 37°C heated 
CO2 incubator (Carl Zeiss, Inc.), EGFP ﬁ  lter set (Omega Optical) and digital 
charge-coupled device camera (C4742-95-12ERG; Hamamatsu). Image 
sequences were acquired with Openlab 3.1.2 software (PerkinElmer). 
Confocal images were acquired with a scanning confocal microscope (DM 
RXA2 with TCS SP2 AOBS head; Leica) using a 40× NA 1.25 objective 
(Leica). Fluorescence quantiﬁ   cation of phospho-Smad staining in nuclei 
was automated with a self-developed routine in MetaMorph (Visitron Systems). 
In brief, nuclei were outlined by regions of interest by image thresholding 
and ﬂ  uorescence was calculated per unit area, corrected for image back-
ground ﬂ  uorescence. Mean values ± SD were calculated from 10 images 
per condition performed in triplicate ( 1,000 nuclei per condition). Kymo-
graphs were produced from image sequences as described previously 
(Hinz et al., 1999) using MetaMorph and ﬁ  gures were assembled with 
Photoshop (Adobe).
Stretchable culture membranes and tunable compliant and wrinkling 
culture substrates
Cells were stretched isoaxially by 3–10% in home-made culture devices 
with silicone membranes at the bottom (Gofﬁ  n et al., 2006). Compliant 
culture substrates were generated and calibrated as described previously 
(Gofﬁ  n et al., 2006) with a Young’s modulus of  47 and 5 kPa, respectively, 
as determined by atomic force microscopy (Nanowizard II; JPK Instruments; 
Gofﬁ  n et al., 2006). Wrinkling silicone substrates to visualize cell contraction 
were prepared as described previously (Hinz et al., 2001a). All surfaces 
were activated for cell attachment by covalent linking of 10 μg/ml of collagen 
type I (Sigma-Aldrich; Gofﬁ  n et al., 2006).
Generation of Mf-derived ECM and TX-100–extracted cytoskeletons
To prepare ECM, cultures were extracted two times for 5 min with 0.5% 
DOC in radio immunoprecipitation assay buffer (50 mM Tris, 150 mM 
NaCl, and 1% Nonidet P-40) under gentle shaking (Unsold et al., 2001). 
Membrane- and cytosol-free cytoskeletons were produced by extracting cells 
two times for 15 min with TX-100–containing buffer (60 mM Pipes, 25 mM 
Hepes, 2 mM MgCl2, 1 mM sodium orthovanadate, 1 mM PMSF, and 0.5% 
TX-100, pH 6.9) under gentle shaking (Dugina et al., 2001); all steps were 
performed with ice-cold solutions at 4°C.
TGF-𝗃 bioassay
To quantify active TGF-β, we used TMLC to produce luciferase under con-
trol of the PAI-1 promoter in response to TGF-β (Abe et al., 1994). TMLC 
(50,000 cells/cm
2) were grown for 4 h before being exposed to TGF-β1 in 
0.1% BSA in serum-free medium. TMLC were immersed with culture-derived 
medium, directly co-cultured with experimental cells, or grown in a sand-
wich assay (Fig. 5 A). In selected experiments, the level of total TGF-β was 
assessed by heat-activating samples for 10 min at 80°C (Abe et al., 1994). 
After exposure to TGF-β1, TMLC were incubated for further 14 h and lysed, 
and luciferase activity was assessed by light production from a luciferin 
substrate (Promega) using a luminometer (Centro LB; Berthold Technologies). 
If not stated otherwise, all results were corrected for TMLC luciferase pro-
duction in the absence of TGF-β1 (approximately ﬁ  ve times lower than that 
produced by nonstimulated lung Mfs) and are presented as mean ± SD of JCB • VOLUME 179 • NUMBER 6 • 2007  1322
one representative experiment performed in triplicate. Experiments were 
performed a minimum of ﬁ  ve times.
Online supplemental material
Fig. S1 illustrates the evolution of tension generated by Mfs grown on 
silicone wrinkling substrates upon treatment with thrombin and SMA-FP. 
Video 1 shows the corresponding cell movements. Fig. S2 shows that 100 mM 
of DGR or RGD peptides preserves the integrity of cytoskeleton and focal 
adhesion organization. Video 2 demonstrates the contraction of TX-100–
puriﬁ  ed, Mf-derived cytoskeleton upon addition of ATP. Video 3 presents 
the deformation of LTBP-1 ﬁ  bers in thrombin-stimulated Mf cultures grown 
on 5-kPa soft silicone substrate; a close-up of a single ﬁ  ber is available 
in Video 5. The deformation of LTBP-1 ﬁ  bers in thrombin-stimulated Mf 
cultures grown on 47-kPa hard silicone substrate is shown in Video 4; 
a close-up of a single ﬁ  ber is available in Video 6. Fig. S3 shows that 
com  ponents of the TGF-β1 signaling cascade are differentially phosphory-
lated in rat wound granulation tissue subjected to different levels of stress. 
Online supplemental material is available at http://www.jcb.org/cgi/
content/full/jcb.200704042/DC1.
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